◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksH › HDST-M

HBL - Hadasit Bio-Holdings Ltd (HDST-M) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-22

HBL - Hadasit Bio-Holdings Ltd (HDST-M) operates in the Biotechnology industry and is headquartered in Jerusalem, Israel with about 1 employees. Its market capitalization is roughly ₪7 million. In the fiscal year ended 2025-12-31, HDST-M reported ₪0M in revenue and (₪2M) in net income.

HBL - Hadasit Bio-Holdings Ltd engages in the medical and biotechnology research and development activities in Israel. The company's portfolios are developing novel protein drugs for cancer immunotherapy and stem cell-based therapies for the treatment of eye diseases.

Interactive charts & full statements →

HDST-M Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue₪0M₪0M₪0M₪0M
Operating Income (EBIT)(₪2M)(₪2M)(₪2M)(₪3M)
Net Income(₪2M)(₪4M)(₪29M)(₪31M)

ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.

HDST-M Free Cash Flow History

HDST-M Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets₪2M₪3M₪8M₪39M
Total Liabilities₪2M₪1M₪3M₪4M

ILS; ₪M / ₪B as marked. Newest period first. Source: company filings via the Israel Securities Authority’s Magna disclosure system.

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive HDST-M viewer.

Other Companies in Biotechnology

This page in other languages: עברית

← HDSNAll “H” companiesHDUS →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.